Odyssey Therapeutics IPO
Odyssey Therapeutics is a biotechnology company developing precision medicines for cancer and autoimmune diseases using proprietary computational and experimental platforms. The company's IPO potential stems from its innovative drug discovery approach and pipeline of novel therapeutics targeting significant unmet medical needs.
Key Facts
| Industry | Biotechnology |
| Founded | 2020 |
| Headquarters | Boston, MA |
| Funding | Series B funding raised (amount not publicly disclosed). Successfully completed IPO on May 8, 2026, raising approximately $279-304 million at $18 per share (high end of range) in an upsized offering. |
About Odyssey Therapeutics
Odyssey Therapeutics is a biotechnology company founded to develop precision medicines for patients with cancer and autoimmune diseases. The company utilizes a proprietary platform that integrates computational design with experimental validation to discover novel therapeutics with optimized properties for their intended targets.
The company's approach focuses on addressing challenging biological targets that have been difficult to drug using traditional methods. By combining advanced computational modeling, structural biology, and medicinal chemistry, Odyssey aims to design molecules with superior efficacy, selectivity, and pharmacological properties. The company has built a pipeline spanning multiple therapeutic areas with the goal of bringing transformative treatments to patients with serious diseases.
IPO Status
Odyssey Therapeutics successfully completed its initial public offering on May 8, 2026, beginning trading on Nasdaq under the ticker symbol ODTX. The company priced its upsized IPO at $18 per share, the high end of its anticipated range, raising approximately $279-304 million (sources vary on exact amount due to concurrent private placement). The stock climbed 11% on its first day of trading, reflecting strong investor interest in the autoimmune disease-focused biotech. Founded by notable biotech entrepreneurs and backed by leading life sciences investors, Odyssey has developed a platform combining computational drug design with traditional medicinal chemistry. The company focuses on autoimmune diseases and has generated particular interest for its ulcerative colitis program. The CEO has described the IPO as an opportunity to create a 'little large pharma,' indicating ambitious plans to advance its drug development pipeline in oncology and immunology indications using the newly raised public market capital.
Competitors
Frequently Asked Questions
Does Odyssey Therapeutics have a stock?
No, Odyssey Therapeutics has not had an IPO yet. The company is currently private but is expected to consider public markets as it advances its drug development programs. Sign up for alerts to stay informed.
When is the Odyssey Therapeutics IPO date?
No specific IPO date has been announced for Odyssey Therapeutics. While there is expectation the company may go public in the future, no official timeline has been confirmed. Sign up for alerts to stay informed.
How can I buy Odyssey Therapeutics stock?
Odyssey Therapeutics stock is not currently available to purchase as the company remains private. Once it goes public, shares would be accessible through standard brokerage accounts. Sign up for alerts to stay informed.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts